Lymphoma clinical trials near Vancouver

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Recruiting nowPhase 15 sites

The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Recruiting nowPhase 113 sites

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory N…

Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma

Opening soon1 site

Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities. Ultra-low dose RT (4Gy in 2 fractions) has minimal toxicity but lower disea…

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting nowPhase 372 sites

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New …

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting nowPhase 218 sites

This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Recruiting nowPhase 3277 sites

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviva…

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Recruiting nowPhase 334 sites

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lym…

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Recruiting nowPhase 22 sites

The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Recruiting now428 sites

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer e…

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Recruiting nowPhase 28 sites

This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this…

Common questions

How do I find a lymphoma clinical trial near me in Canada?

Use Beacon's free search: enter "lymphoma", your age, and your location, and you'll see recruiting trials sorted by distance, each explained in plain language — including sites just across the US border. Beacon searches the full official registry and never requires an account.

Does joining a clinical trial cost money?

The study treatment and study-related tests are usually provided at no cost, and some trials help with travel. In Canada, your provincial health coverage continues to apply to your routine care — always confirm details with the study team.

Can I leave a clinical trial after joining?

Yes. Participation is always voluntary, and you can leave a trial at any time, for any reason, without losing your normal medical care.

Do I qualify for these trials?

Every trial has its own eligibility criteria. Beacon translates each trial's criteria into a plain-language checklist you can review and bring to your doctor — only the study team can confirm whether you qualify.